Liu Yi - Kura Oncology Insider

Kura Oncology -- USA Stock  

USD 17.45  0.45  2.51%

Co-Founder, Chief Scientific Officer

Dr. Yi Liu, Ph.D. is Chief Scientific Officer of Kura Oncology, Inc. Since March 2015. Dr. Liu cofounded Prior Kura in August 2014 and served as the Chief Scientific Officer of Prior Kura from October 2014 until the Upstream Merger in March 2015. Prior to that, Dr. Liu cofounded and served as Chief Scientific Officer of Wellspring Biosciences LLC, a private biopharmaceutical company, from July 2012 to September 2014. Dr. Liu also cofounded Intellikine, Inc., a private biopharmaceutical company, where he served as Vice President of Drug Discovery from 2007 to May 2012, until its acquisition by Takeda Pharmaceutical Company Limited. Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation. Earlier in his career, he held senior scientist positions at both SGX Pharmaceuticals, Inc., a public biopharmaceutical company which was acquired by Eli Lilly and Company in 2008, and Curagen Corporationrationration, a public biopharmaceutical development company
Age: 46  Founder Since 2015      
858-500-8800  http://www.kuraoncology.com
Liu received his Ph.D. in Biochemistry from Princeton University, his MSc in computational chemistry from Beijing University and his BE in Chemical Engineering from Tsinghua University.

Management Efficiency

The company has return on total asset (ROA) of (27.22) % which means that it has lost $27.22 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (51.83) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 7.1 M in liabilities with Debt to Equity (D/E) ratio of 8.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kura Oncology has Current Ratio of 9.25 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. The company was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in USA and traded on NASDAQ. It employs 31 people.Kura Oncology (KURA) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 31 people. Kura Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.

Kura Oncology Leadership Team

Troy Wilson, Chairman
Steven Stein, Director
Faheem Hasnain, Director
Annette North, President
Liu Yi, Founder
Thomas Malley, Director
Pingda Ren, SVP, Ph.D
Antonio Gualberto, Executive, Ph.D
Heidi Henson, CFO
Robert Hoffman, Director, CPA

Stock Performance Indicators

Current Sentiment - KURA

Kura Oncology Investor Sentiment
Most of Macroaxis users are now bullish on Kura Oncology. What is your trading attitude regarding investing in Kura Oncology? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip  Hide

Generate Optimal Portfolios

Align your risk and return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.